Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.
作者信息
Loomba Rohit, Seguritan Victor, Li Weizhong, Long Tao, Klitgord Niels, Bhatt Archana, Dulai Parambir Singh, Caussy Cyrielle, Bettencourt Richele, Highlander Sarah K, Jones Marcus B, Sirlin Claude B, Schnabl Bernd, Brinkac Lauren, Schork Nicholas, Chen Chi-Hua, Brenner David A, Biggs William, Yooseph Shibu, Venter J Craig, Nelson Karen E
出版信息
Cell Metab. 2019 Sep 3;30(3):607. doi: 10.1016/j.cmet.2019.08.002.
Abstract
摘要
相似文献
1
Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.基于肠道微生物群的宏基因组特征用于非侵入性检测人类非酒精性脂肪性肝病中的晚期纤维化
Cell Metab. 2019 Sep 3;30(3):607. doi: 10.1016/j.cmet.2019.08.002.
2
Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.基于肠道微生物群的宏基因组特征用于非侵入性检测人类非酒精性脂肪性肝病中的晚期纤维化
Cell Metab. 2017 May 2;25(5):1054-1062.e5. doi: 10.1016/j.cmet.2017.04.001.
3
A Microbial Signature Identifies Advanced Fibrosis in Patients with Chronic Liver Disease Mainly Due to NAFLD.一种微生物特征可识别主要由非酒精性脂肪性肝病引起的慢性肝病患者的晚期纤维化。
Sci Rep. 2020 Feb 17;10(1):2771. doi: 10.1038/s41598-020-59535-w.
4
A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis.一种通用的肠道微生物组衍生特征可预测肝硬化。
Cell Metab. 2020 Nov 3;32(5):878-888.e6. doi: 10.1016/j.cmet.2020.06.005. Epub 2020 Jun 30.
5
The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.非酒精性脂肪性肝病的严重程度与肠道菌群失调及肠道微生物群代谢功能的改变有关。
Hepatology. 2016 Mar;63(3):764-75. doi: 10.1002/hep.28356. Epub 2016 Jan 13.
6
Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease.肠道病毒组特征与非酒精性脂肪性肝病严重程度相关。
Gastroenterology. 2020 Nov;159(5):1839-1852. doi: 10.1053/j.gastro.2020.07.005. Epub 2020 Jul 9.
7
Gut microbiome changes in Nonalcoholic fatty liver disease & alcoholic liver disease.非酒精性脂肪性肝病和酒精性肝病中的肠道微生物群变化
Transl Gastroenterol Hepatol. 2021 Jan 5;6:3. doi: 10.21037/tgh.2020.02.18. eCollection 2021.
8
A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease.非酒精性脂肪性肝病相关肝硬化的肠道微生物组特征。
Nat Commun. 2019 Mar 29;10(1):1406. doi: 10.1038/s41467-019-09455-9.
9
Prediction of advanced fibrosis in non-alcoholic fatty liver disease using gut microbiota-based approaches compared with simple non-invasive tools.基于肠道微生物组的方法与简单的无创工具相比，预测非酒精性脂肪性肝病的肝纤维化程度。
Sci Rep. 2020 Jun 10;10(1):9385. doi: 10.1038/s41598-020-66241-0.
10
Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications.综述文章：肠道微生物组在非酒精性脂肪性肝病进展中的新作用及其潜在的治疗意义。
Aliment Pharmacol Ther. 2019 Jul;50(2):144-158. doi: 10.1111/apt.15314. Epub 2019 May 31.
引用本文的文献
1
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes.代谢功能障碍相关脂肪性肝病（MASLD）：肠道微生物群、胰岛素抵抗和糖尿病之间的相互作用
Front Med (Lausanne). 2025 Aug 14;12:1618275. doi: 10.3389/fmed.2025.1618275. eCollection 2025.
2
Gut microbiota and metabolomics in metabolic dysfunction-associated fatty liver disease: interaction, mechanism, and therapeutic value.代谢功能障碍相关脂肪性肝病中的肠道微生物群与代谢组学：相互作用、机制及治疗价值
Front Cell Infect Microbiol. 2025 Jul 23;15:1635638. doi: 10.3389/fcimb.2025.1635638. eCollection 2025.
3
Understanding crosstalk between the gut and liver microbiome: pathogenesis to therapeutic approaches in liver cancer.了解肠道和肝脏微生物群之间的串扰：肝癌的发病机制与治疗方法
Cancer Cell Int. 2025 Jul 29;25(1):291. doi: 10.1186/s12935-025-03840-9.
4
Analysis of gut and circulating microbiota characteristics in patients with liver cirrhosis and portal vein thrombosis.肝硬化合并门静脉血栓形成患者肠道及循环微生物群特征分析
Front Microbiol. 2025 Jun 19;16:1597145. doi: 10.3389/fmicb.2025.1597145. eCollection 2025.
5
The newly proposed dietary index for gut microbiota and its association with the risk of nonalcoholic fatty liver disease: the mediating role of body mass index.新提出的肠道微生物群饮食指数及其与非酒精性脂肪性肝病风险的关联：体重指数的中介作用。
Diabetol Metab Syndr. 2025 Jun 21;17(1):237. doi: 10.1186/s13098-025-01801-w.
6
Meta-analysis of shotgun sequencing of gut microbiota in obese children with MASLD or MASH.对患有MASLD或MASH的肥胖儿童肠道微生物群进行鸟枪法测序的荟萃分析。
Gut Microbes. 2025 Dec;17(1):2508951. doi: 10.1080/19490976.2025.2508951. Epub 2025 May 21.
7
The microenvironment in the development of MASLD-MASH-HCC and associated therapeutic in MASH-HCC.代谢相关脂肪性肝病-代谢相关脂肪性肝炎-肝细胞癌（MASLD-MASH-HCC）发生发展中的微环境及MASH-HCC的相关治疗
Front Immunol. 2025 Apr 30;16:1569915. doi: 10.3389/fimmu.2025.1569915. eCollection 2025.
8
Unlocking the gut-liver axis: microbial contributions to the pathogenesis of metabolic-associated fatty liver disease.揭示肠-肝轴：微生物在代谢相关脂肪性肝病发病机制中的作用
Front Microbiol. 2025 Apr 25;16:1577724. doi: 10.3389/fmicb.2025.1577724. eCollection 2025.
9
The Role of the Gut-Biliary-Liver Axis in Primary Hepatobiliary Liver Cancers: From Molecular Insights to Clinical Applications.肠道-胆管-肝脏轴在原发性肝胆管癌中的作用：从分子洞察到临床应用
J Pers Med. 2025 Mar 24;15(4):124. doi: 10.3390/jpm15040124.
10
Research progress on fecal microbiota transplantation in tumor prevention and treatment.粪便微生物群移植在肿瘤防治中的研究进展
Open Life Sci. 2025 Apr 1;20(1):20220954. doi: 10.1515/biol-2022-0954. eCollection 2025.
Zotero 插件